stockrow
Friday 6 November 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
7.55
0.69
−8.37%
Follow BCRX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
7 | 3 | 4 | 3 | 5 | 2 | 3 | 2 | 5 | 2 |
P/S ratio |
1.87 | 3.45 | 3.52 | 7.86 | 15.78 | 69.96 | 8.17 | 40.32 | 18.24 | 17.79 |
Altman Z-Score |
1.83 | (2.55) | (3.06) | (1.69) | (0.52) | (3.06) | (6.07) | (3.47) | (2.91) | (6.97) |
P/FCF ratio |
4.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.63) | (8.82) | (8.05) | (5.90) | (3.73) | (9.26) | (16.46) | (18.03) | (10.93) | (23.23) |
Beneish M-Score |
(2.27) | (0.91) | (3.82) | (2.23) | 4.12 | (4.64) | (0.91) | (3.57) | (3.09) | (2.04) |
P/Operating CF |
5.61 | (298.17) | (130.82) | (89.26) | (76.43) | (29.30) | (38.17) | (34.72) | (43.67) | (80.07) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43 | 16.91 | 5.48 | 297.04 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43 | 16.91 | 5.48 | 297.04 |
EV/Sales |
2.11 | 4.58 | 4.87 | 9.01 | 16.31 | 68.66 | 6.45 | 36.77 | 14.60 | 16.62 |
EV/EBITDA |
5.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
5.31 | (39.68) | (16.96) | (15.08) | (18.03) | (9.05) | (3.51) | (8.20) | (8.94) | (8.20) |
EV/FCF |
5.34 | (38.84) | (16.58) | (14.95) | (17.73) | (9.02) | (3.50) | (8.17) | (8.87) | (7.46) |
Quick Ratio |
1.95 | 2.49 | 2.99 | 4.51 | 5.21 | 2.95 | 1.73 | 1.59 | 1.65 | 1.20 |
Current Ratio |
2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
Net Debt/EBITDA |
0.61 | (39.91) | (3.98) | (2.09) | (0.47) | 0.13 | 0.85 | 0.79 | 1.65 | 0.05 |
Debt/Assets |
93.53% | 169.39% | 162.04% | 134.08% | 100.86% | 83.50% | 30.64% | 22.24% | 14.57% | 59.79% |
Debt/Equity |
(4.04) | (1.75) | (1.84) | (2.50) | (5.54) | (14.51) | 1.40 | 0.66 | 0.31 | 34.05 |
Asset Turnover |
1.74 | 0.89 | 0.62 | 0.48 | 0.34 | 0.07 | 0.30 | 0.13 | 0.19 | 0.25 |
Operating CF/Net income |
1.32 | 0.59 | 0.42 | 0.66 | 0.77 | 0.74 | 0.82 | 0.91 | 0.63 | 0.97 |
Capex/Depreciation |
0.65 | 0.11 | 0.25 | 3.97 | (3.08) | (0.59) | (0.41) | (0.21) | (0.18) | (3.37) |
Interest Coverage |
4.32 | (0.03) | (0.96) | (1.50) | (3.00) | (12.05) | (8.36) | (10.27) | (6.70) | (7.49) |
| (88.68%) | 19.08% | 60.40% | 123.07% | 291.59% | (1,925.37%) | (248.94%) | (152.26%) | (154.16%) | (223.70%) | |
| 52.53% | (17.65%) | (42.46%) | (43.42%) | (39.89%) | (71.69%) | (67.61%) | (62.29%) | (49.07%) | (51.97%) | |
ROIC |
245.61% | (4.71%) | 0.00% | (544.24%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
121.56% | (33.00%) | (64.01%) | (58.89%) | (39.07%) | (81.16%) | (137.22%) | (187.47%) | (109.45%) | (244.55%) |
Average Days of Receivables |
44.57 | 64.03 | 62.72 | 68.19 | 68.31 | 177.17 | 165.52 | 75.87 | 88.65 | 121.44 |
Research and Development Expense of Revenue |
18.99% | 38.75% | 65.35% | 93.53% | 132.85% | 690.34% | 219.24% | 411.02% | 265.87% | 231.50% |
Selling, General and Administrative Expense of Revenue |
39.85% | 59.09% | 64.59% | 58.85% | 75.60% | 381.37% | 76.01% | 142.90% | 55.32% | 42.70% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.72% | 14.51% | 16.78% | 16.51% | 22.04% | 83.06% | 36.28% | 45.49% | 50.11% | 32.21% |
Graham Net Nets |
(0.14) | (0.35) | (0.41) | (0.15) | (0.05) | (0.02) | 0.07 | 0.02 | 0.07 | (0.05) |
Graham Number |
0.00 | 4.72 | 7.93 | 6.89 | 3.72 | 1.67 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
16.03% | (5.72%) | (19.44%) | (11.62%) | (7.44%) | (14.50%) | (28.41%) | (12.14%) | (14.34%) | (11.79%) |
Free Cash Flow Yield |
21.10% | (3.42%) | (8.34%) | (7.67%) | (5.83%) | (10.88%) | (22.55%) | (11.16%) | (9.02%) | (12.53%) |
Revenue per Share |
4.17 | 2.18 | 1.72 | 1.46 | 0.88 | 0.11 | 0.42 | 0.20 | 0.30 | 0.36 |
Operating CF per Share |
1.66 | (0.25) | (0.49) | (0.87) | (0.79) | (0.81) | (0.77) | (0.90) | (0.49) | (0.73) |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.07) |
Free Cash Flow per Share |
1.65 | (0.26) | (0.51) | (0.88) | (0.81) | (0.81) | (0.78) | (0.90) | (0.49) | (0.80) |
Cash per Share |
1.31 | 1.55 | 2.03 | 2.29 | 2.85 | 1.81 | 1.19 | 1.03 | 1.39 | 0.76 |
Shareholders Equity per Share |
(0.57) | (2.30) | (2.37) | (1.58) | (0.60) | (0.12) | 0.33 | 0.48 | 0.99 | 0.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.57) | (2.30) | (2.37) | (1.58) | (0.60) | (0.12) | 0.33 | 0.48 | 0.99 | 0.02 |
Free Cash Flow |
345.45 | (53.14) | (97.31) | (163.20) | (144.54) | (135.62) | (89.93) | (92.93) | (41.46) | (58.71) |
Working Capital |
208.28 | 261.58 | 345.98 | 410.99 | 462.42 | 218.15 | 72.01 | 44.88 | 50.56 | 12.63 |
Capital Expenditures |
(1.92) | (1.12) | (2.17) | (1.35) | (2.38) | (0.51) | (0.34) | (0.37) | (0.32) | (5.27) |
Net Current Asset Value |
(228.96) | (544.39) | (476.52) | (328.10) | (129.00) | (30.18) | 27.32 | 16.75 | 30.90 | (21.28) |
EV/EBIT |
5.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.02 | 0.01 | 0.20 |
Price to Operating Income |
4.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.33) | (1.31) | (1.09) | (0.04) | 0.09 | 0.12 | 0.11 | 0.19 | 0.18 | 0.16 |
Cash ROIC |
54.26% | (7.86%) | (12.59%) | (18.79%) | (14.49%) | (24.10%) | (39.14%) | (49.46%) | (18.23%) | (52.66%) |
Accounts Receivable Turnover |
9.41 | 6.63 | 6.16 | 6.77 | 8.26 | 1.16 | 3.69 | 3.97 | 3.38 | 3.51 |
Accounts Payable Turnover |
1.39 | 0.75 | 0.25 | 0.30 | 0.31 | 0.09 | 0.34 | 0.12 | 0.22 | 0.34 |
Inventory Turnover |
2.83 | 0.67 | 0.16 | 0.30 | 0.63 | 0.36 | 2.26 | 0.80 | 2.28 | 2.18 |
Average Days of Payables |
302.83 | 346.41 | 1,701.84 | 817.72 | 1,404.06 | 4,406.61 | 1,370.27 | 3,312.72 | 2,025.40 | 678.36 |
Days of Inventory on Hand |
103.29 | 240.59 | 2,336.37 | 1,568.28 | 797.30 | 1,657.57 | 161.54 | 703.14 | 159.81 | 79.45 |
Average Receivables |
92.94 | 68.01 | 53.77 | 40.01 | 19.03 | 15.40 | 13.22 | 5.21 | 7.44 | 7.51 |
Average Payables |
13.74 | 16.27 | 17.62 | 21.08 | 23.26 | 16.35 | 10.88 | 7.05 | 5.30 | 6.79 |
Average Inventory |
6.74 | 18.39 | 28.11 | 21.66 | 11.42 | 4.34 | 1.65 | 1.07 | 0.50 | 1.06 |
Average Assets |
502.29 | 503.69 | 533.48 | 569.08 | 461.43 | 255.00 | 161.06 | 162.55 | 134.05 | 106.10 |
Average Common Equity |
(297.54) | (465.73) | (375.06) | (200.79) | (63.12) | 9.50 | 43.74 | 66.50 | 42.67 | 24.65 |
Columns are period end dates · fundamentals updated 4 Nov 2026